| [11C]AZ1419 3391 + Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [68Ga]Ga-OncoACP3 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abemaciclib for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ABIRATERONE ACETATE + Prednisone for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| abiraterone acetate with prednisone + Tinengotinib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Acupuncture + Questionnaires for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adaptive Hypofractionated Radiotherapy for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AMXI-5001:Dose Escalation Phase I + AMXI-5001:Dose Expansion Phase II for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Placebo for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy + Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aspirin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin + Aspirin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Berzosertib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Cystoscopy + Bone Scan + Digital Rectal Examination + MRI-Guided Transurethral Ultrasound Ablation + Multiparametric Magnetic Resonance Imaging + PSMA PET Scan + Questionnaire Administration for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cardio-Oncology Referral for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clomiphene Citrate 25mg for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| D Vitamin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Darolutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Disitamab for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Disitamab + ENVAFOLIMAB for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| dMD-002 for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enoblituzumab for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Enzalutamide + Mevrometostat for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + PEMBROLIZUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + Tinengotinib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ETX-19477 for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exercise Intervention for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exercise Therapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Experimental for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fasudil hydrochloride combined with immunotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FLUDEOXYGLUCOSE F-18 + PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical) for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Focal One high intensity focused ultrasound device for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GALLIUM GA-68 GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| GALUNISERTIB + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GSK5471713 for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| INR101 for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JNJ-101556143 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Hypofractionated Radiation Therapy + Positron Emission Tomography + Survey Administration for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Positron Emission Tomography + Stereotactic Body Radiation Therapy + Survey Administration for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Multiparametric Magnetic Resonance Imaging + Positron Emission Tomography + Transrectal Ultrasonography Guided Biopsy + Flotufolastat F-18 Gallium for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MR-Guided Transurethral US Ablation of Prostate Tissue for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MRI-Guided Transurethral Ultrasound Ablation for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NanoKnife System for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NeuroSAFE procedure for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Padeliporfin for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Datopotamab Deruxtecan for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Temozolomide for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PIFLUFOLASTAT F-18 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prostate Radiotherapy + Radical Prostatectomy for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PSMA-guided Salvage Radiation for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| QLH12016 + Enzalutamide + ABIRATERONE ACETATE for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Questionnaires + Waitlist Control for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy + Radical Prostatectomy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Olaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Relugolix for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Risvutatug rezetecan (Ris-Rez) for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Robot-Assisted Radical Prostatectomy + ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rocuronium 1.5mg/kg/hr for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care SBRT and ADT + ABIRATERONE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| talazoparib plus enzalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Telesurgery utilizing Microport Medbot Robotic Platform for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Terbium 161- PSMA I&T for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Testosterone for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| treatment with focal HIFU for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Triptorelin pamoate for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TULSA Procedure for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tulsa-pro for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| vitamin D 25(OH)D for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Xaluritamig for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|